Chapter 6 124 Magnesium citrate (n =46) Magnesium oxide (n =46) Magnesium sulfate (n =46) Placebo (n =26) 12-wk Mean, mm Hg 96 ± 11 92 ± 9 95 ± 9 96 ± 10 Difference vs placebo 0 (-2; 3) -0 (-3; 2) 0 (-2; 3) . . 24-wk Mean, mm Hg 97 ± 11 93 ± 10 96 ± 11 96 ± 10 Difference vs placebo 0 (-2; 3) 1 (-2; 3) 1 (-2; 3) . . Pulse pressure 2-wk Mean, mm Hg 53 ± 9 50 ± 10 51 ± 10 50 ± 8 Difference vs placebo -0 (-3; 3) 0 (-3; 3) 1 (-2; 4) . . 12-wk Mean, mm Hg 53 ± 10 49 ± 9 51 ± 9 48 ± 6 Difference vs placebo 3 (-0; 6) 2 (-1; 5) 2 (-1; 5) . . 24-wk Mean, mm Hg 54 ± 10 51 ± 11 52 ± 10 49 ± 6 Difference vs placebo 2 (-1; 5) 2 (-1; 5) 3 (-0; 6) . . Heart rate 2-wk Mean, bpm 61 ± 8 59 ± 8 59 ± 7 62 ± 7 Difference vs placebo -0 (-3; 2) -1 (-4; 1) -1 (-3; 2) . . 12-wk Mean, bpm 61 ± 8 59 ± 7 60 ± 6 61 ± 8 Difference vs placebo -0 (-3; 2) -2 (-4; 1) -1 (-3; 2) . . 24-wk Mean, bpm 62 ± 8 59 ± 7 59 ± 6 62 ± 7 Difference vs placebo 0 (-2; 3) -3 (-5; -0)* -1 (-4; 1) . . Values are mean ± SD. Adjusted mean differences (95% CIs) were obtained from linear mixedeffect models with age, sex, baseline value of the outcome of interest, time, intervention, and the interaction time × intervention as fixed effects. SBP; systolic blood pressure, DBP; diastolic blood pressure, MAP; mean arterial pressure, PP; pulse pressure, HR; heart rate. * P < 0.05 (two-sided P values). Magnesium oxide vs Magnesium citrate During the treatment period, vascular function markers (Table 5) and blood pressure (Table 6) were not different between the magnesium oxide and magnesium citrate group. Heart rate was significantly lower in the magnesium oxide group by 3 bpm at 24-wk (90% CI: 1; 5 bpm). Plasma magnesium was similar among the two magnesium groups,whereas 24-h urinarymagnesium excretion was slightly lower in the magnesium Table 3. (Continued)
RkJQdWJsaXNoZXIy MTk4NDMw